CONTRIBUTION OF PLATELETS AND PLATELET-ACTIVATING-FACTOR (PAF) TO THE ARRHYTHMOGENIC, HEMODYNAMIC AND NECROTIC EFFECTS OF ACUTE MYOCARDIAL-ISCHEMIA

被引:29
作者
CHAKRABARTY, S [1 ]
THOMAS, P [1 ]
SHERIDAN, DJ [1 ]
机构
[1] ST MARYS HOSP,SCH MED,ACAD CARDIOL UNIT,LONDON W2 1PG,ENGLAND
关键词
MYOCARDIAL ISCHEMIA; PLATELETS; PLATELET ACTIVATING FACTOR;
D O I
10.1093/oxfordjournals.eurheartj.a059944
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of alterations in platelet activity on arrhythmias, haemodynamics and extent of necrosis during coronary ligation for 30 min were assessed in rabbits. Reductions of platelet counts to less than 1% of control by intravenous injection of platelet antiserum (1 ml kg-1 i.v.) reduced the volume of necrosed tissue from 23±2% to 15±1%, P <0·07 (expressed as % of total LV) and attenuated the hypotensive effect of ischaemia. Pretreatment with the platelet activating factor (PAF) antagonist BN 52021 also attenuated the hypotension and necrosis caused by coronary ligation 23±2% vs 14±1%, P<0·01. Pretreatment with the thromboxane antagonist CGS 13080 attenuated the hypotensive response to ischaemia but had only a very small effect on the area of necrosis. Administration of PAF at 10 min following coronary ligation markedly increased the volume of necrosed tissue 36±2%, P<0·01 and caused VF and haemodynamic collapse in 10 out of 12 animals. Pretreatment with platelet antiserum or the PAF antagonist BN 52021 reversed this effect of PAF. Pretreatment with CGS 13080 attenuated the marked hypotensive effect of PAF but failed to reverse its necrotic or arrhythmogenic effects. These findings indicate that platelet activation contributes to the necrosis and hypotension following coronary ligation and that platelet-activating factor may contribute to this. The ameliorating effects of platelet antiserum or BN 52021 support the concept that inhibition of platelet activity may have a useful role in the treatment of acute myocardial infarction. © 1991 The European Society of Cardiology.
引用
收藏
页码:583 / 589
页数:7
相关论文
共 42 条
[1]   EFFECT OF PLATELET-ACTIVATING-FACTOR (PAF) ON HUMAN CARDIAC-MUSCLE [J].
ALLOATTI, G ;
MONTRUCCHIO, G ;
MARIANO, F ;
TETTA, C ;
DEPAULIS, R ;
MOREA, M ;
EMANUELLI, G ;
CAMUSSI, G .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1986, 79 (01) :108-112
[2]   PLATELET-ADHESION, RELEASE AND AGGREGATION IN FLOWING BLOOD - EFFECTS OF SURFACE PROPERTIES AND PLATELET-FUNCTION [J].
BAUMGARTNER, HR ;
MUGGLI, R ;
TSCHOPP, TB ;
TURITTO, VT .
THROMBOSIS AND HAEMOSTASIS, 1976, 35 (01) :124-138
[3]   LEUKOCYTE-DEPENDENT HISTAMINE-RELEASE FROM RABBIT PLATELETS - ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR [J].
BENVENISTE, J ;
HENSON, PM ;
COCHRANE, CG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1972, 136 (06) :1356-+
[4]   THE ACTIONS OF PAF-ACETHER (PLATELET-ACTIVATING FACTOR) ON GUINEA-PIG ISOLATED HEART PREPARATIONS [J].
BENVENISTE, J ;
BOULLET, C ;
BRINK, C ;
LABAT, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 80 (01) :81-83
[5]   ACUTE CIRCULATORY COLLAPSE CAUSED BY PLATELET-ACTIVATING FACTOR (PAF-ACETHER) IN DOGS [J].
BESSIN, P ;
BONNET, J ;
APFFEL, D ;
SOULARD, C ;
DESGROUX, L ;
PELAS, I ;
BENVENISTE, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 86 (3-4) :403-413
[6]  
BURKE JE, 1983, BR J CLIN PHARM, V15, P975
[7]   PROTECTION OF ISCHEMIC CAT MYOCARDIUM BY CGS-13080, A SELECTIVE POTENT THROMBOXANE-A2 SYNTHESIS INHIBITOR [J].
BURKE, SE ;
DICOLA, G ;
LEFER, AM .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1983, 5 (05) :842-847
[8]   RELEASE OF PLATELET-ACTIVATING-FACTOR FROM RABBIT HEART PERFUSED INVITRO BY SERA WITH TRANSPLANTATION ALLOANTIBODIES [J].
CAMUSSI, G ;
NIESEN, N ;
TETTA, C ;
SAUNDERS, RN ;
MILGROM, F .
TRANSPLANTATION, 1987, 44 (01) :113-118
[9]  
CAZENAVE JP, 1979, LAB INVEST, V41, P275
[10]   ROLE OF PLATELET-ACTIVATING FACTOR IN PLATELET-AGGREGATION [J].
CHIGNARD, M ;
LECOUEDIC, JP ;
TENCE, M ;
VARGAFTIG, BB ;
BENVENISTE, J .
NATURE, 1979, 279 (5716) :799-800